56 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design and synthesis of potent and selective P2X3 receptor antagonists derived from PPADS as potential pain modulators.
Gwangju Institute of Science and Technology (Gist)
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists.
University of Camerino
Synthesis and structure-activity relationships of carboxylic acid derivatives of pyridoxal as P2X receptor antagonists.
Gwangju Institute of Science and Technology
Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.
University of Bonn
Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.
Roche Palo Alto
N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists.
University of Bonn
Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor.
University of Bonn
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.
Abbott Laboratories
Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist.
Institute of Science and Technology
Novel antagonists acting at the P2Y(1) purinergic receptor: synthesis and conformational analysis using potentiometric and nuclear magnetic resonance titration techniques.
Universit£
Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.
Roche Palo Alto
Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.
Roche Palo Alto
Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.
Northwest University
Discovery and synthesis of a novel and selective drug-like P2X(1) antagonist.
Roche Palo Alto
Unveiling the Structure-Activity Relationships at the Orthosteric Binding Site of P2X Ion Channels: The Route to Selectivity.
European Institute For Molecular Imaging (Eimi)
AI-based prediction of new binding site and virtual screening for the discovery of novel P2X3 receptor antagonists.
Gwangju Institute of Science and Technology
Discovery of 5-methyl-1H-benzo[d]imidazole derivatives as novel P2X3 Receptor antagonists.
Gwangju Institute of Science and Technology (Gist)
Structure-Activity Relationship and Neuroprotective Activity of 1,5-Dihydro-2
National Institute of Diabetes and Digestive and Kidney Diseases
Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists.
Shionogi
Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.
Shionogi
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
National Institute of Diabetes and Digestive and Kidney Diseases
Discovery and Structure Relationships of Salicylanilide Derivatives as Potent, Non-acidic P2X1 Receptor Antagonists.
University of Bonn
Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion.
Gwangju Institute of Science and Technology (Gist)
New P2X3 receptor antagonists. Part 2: Identification and SAR of quinazolinones.
Gedeon Richter
New P2X3 receptor antagonists. Part 1: Discovery and optimization of tricyclic compounds.
Gedeon Richter
Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.
Shionogi
Synthesis of Novel Potent Archazolids: Pharmacology of an Emerging Class of Anticancer Drugs.
Universit£T Bonn
A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors.
National Institute of Diabetes and Digestive and Kidney Diseases
Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells.
Gwangju Institute of Science and Technology (Gist)
Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 1: Initial structure-activity relationship studies of a hit from a high throughput screening.
Shionogi
Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.
University of Georgia
Small-Molecule Inhibitors of the SOX18 Transcription Factor.
The University of Queensland
Synthesis of bicyclic molecular scaffolds (BTAa): an investigation towards new selective MMP-12 inhibitors.
University of Florence
Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment.
Wyeth Research
Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Saarland University
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.
Novartis Pharmaceuticals